First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
But results come from a curated dataset, with no in-trial comparator.
A common mutation comes into play for PRMT5 inhibition.
Tolerability could decide first-line therapy in EGFRm disease.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.